Home › Scleroderma › North Carolina
Scleroderma clinical trials in North Carolina
9 studies for Scleroderma are looking for participants at sites in North Carolina.
Cities in North Carolina
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Atrium Health Rheumatology-Southpark, Charlotte
- Duke University Medical Center, Durham
RecruitingPhase 1
Ages 18 to 74 · All sexes · Updated Sep 10, 2026 · NCT07085104A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- University of North Carolina TraCS Institute - CTRC, Chapel Hill
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Aug 28, 2026 · NCT06925542Platform Clinical Study for Conquering Scleroderma
- Duke University Medical Center, Durham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Duke University, Durham
RecruitingPhase 2/3
Ages 18 to 75 · All sexes · Updated Aug 17, 2026 · NCT06328777A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Charlotte
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Aug 7, 2026 · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Charlotte, Charlotte
- Artiva Investigational Site Charlotte, Charlotte
- Artiva Investigational Site Statesville, Statesville
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT06991114A Study of AZD0120 in Autoimmune Diseases
- Research Site, Chapel Hill
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Jul 28, 2026 · NCT07295847A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- Duke University, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 14, 2026 · NCT07115745A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Duke University Health System, Durham
RecruitingPhase 1
Ages 12 to 70 · All sexes · Updated May 22, 2026 · NCT06308978From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.